JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Monica Raines, the Executive Vice President and Chief Compliance and Quality Officer at Addus HomeCare Corp (NASDAQ:ADUS), recently sold shares of the company’s common stock. According to a recent SEC filing, Raines sold 254 shares on February 25, 2025, at a price of $99.73 per share, totaling approximately $25,331. The transaction comes as the $1.73 billion market cap company has seen its stock decline by nearly 15% over the past week, with InvestingPro data indicating the stock is currently in oversold territory.
Following the transaction, Raines retains ownership of 14,882 shares of Addus HomeCare. The sale was conducted under a 10b5-1 trading plan, which is often used by insiders to plan stock transactions in advance and avoid potential conflicts of interest. The transaction was made to satisfy tax obligations related to the vesting of restricted stock awards. Despite recent price weakness, InvestingPro analysis shows the company maintains a GOOD financial health score, with 10+ additional ProTips available to subscribers regarding the company’s valuation and growth prospects.
In other recent news, Addus HomeCare Corporation reported its fourth-quarter 2024 earnings, surpassing expectations with an earnings per share (EPS) of $1.38, compared to the forecasted $1.35. The company’s revenue also exceeded projections, reaching $297.1 million against a forecast of $284.28 million. Despite these positive results, Addus HomeCare’s stock experienced a decline, reflecting investor concerns about broader market conditions. KeyBanc Capital Markets maintained its Overweight rating for Addus HomeCare, emphasizing strong same-store growth in its Personal Care segment and a favorable impact from a rate increase in Illinois. The firm also highlighted the successful integration of the Gentiva acquisition. Meanwhile, Stephens adjusted its price target for Addus HomeCare to $142 from $153, but retained an Overweight rating, citing the company’s robust mergers and acquisitions strategy. Raymond (NSE:RYMD) James reduced its price target to $120 from $140, maintaining an Outperform rating due to potential Medicaid policy changes. These developments suggest that while Addus HomeCare’s financial performance remains strong, uncertainties in the Medicaid policy landscape continue to influence investor sentiment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.